 |
|
The Efficacy and Safety of a Combined Alendronate and Calcitriol Agent (Maxmarvil): A Postmarketing Surveillance Study in Korean Postmenopausal Women with Osteoporosis
Hee-Won Suh, Hyun-Ok Kim, Young Sik Kim, Sung Sunwoo, Jung Ah Lee, Hye-Ree Lee, Byungsung Kim, Dae Hyun Kim, Youn Seon Choi, Yoo Seock Cheong, Keunsang Yum, Yun Jun Yang, Byung-Yeon Yu, Chung Hwan Cho, Sat-Byul Park, Dong Hyeok Shin,
Korean J Fam Med. 2012;33(6):346-355. Published online 2012 Nov 27 DOI: https://doi.org/10.4082/kjfm.2012.33.6.346
|
|
Citations to this article as recorded by
 Fracture Preventing Effects of Maxmarvil® Tablets (Alendronate 5 mg + Calcitriol 0.5 µg) in Patients with Osteoporosis
Jun-Il Yoo, Yong-Chan Ha, Ye-Yeon Won, Kyu-Hyun Yang, Sang-Bum Kim, Ju-Hyung Yoo, Dong-Soo Kim
Journal of Bone Metabolism.2017; 24(2): 91. CrossRef The clinical use of vitamin D metabolites and their potential developments: a position statement from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF)
Luisella Cianferotti, Claudio Cricelli, John A. Kanis, Ranuccio Nuti, Jean-Y. Reginster, Johann D. Ringe, Rene Rizzoli, Maria Luisa Brandi
Endocrine.2015; 50(1): 12. CrossRef
|